PPA
QNCX icon

Parametric Portfolio Associates’s Quince Therapeutics QNCX Stock Holding History

Parametric Portfolio Associates’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-41
Closed -$758K – 3684
2021
Q3 		$758K Buy
41
+5
+14% +$79.5K ﹤0.01% 2920
2021
Q2 		$384K Buy
36
+1
+3% +$8.38K ﹤0.01% 3188
2021
Q1 		$251K Buy
+35
New +$252K ﹤0.01% 3788

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Parametric Portfolio Associates's QNCX Position: Q4 2021 in Review

Parametric Portfolio Associates sold out of Quince Therapeutics (QNCX) in Q4 2021, closing a stake of 41 shares — an estimated $758K sold.

Parametric Portfolio Associates first reported a position in QNCX in Q1 2021 and held it in 3 quarters. The position peaked at $758K in Q3 2021. 98 funds tracked by Wall St. Rank hold QNCX as of Q4 2021.

  • Parametric Portfolio Associates reported no remaining Quince Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 41 Quince Therapeutics shares in Q4 2021, an estimated $758K.
  • Parametric Portfolio Associates first reported a position in Quince Therapeutics in Q1 2021 and held it in 3 quarters.
  • Parametric Portfolio Associates's Quince Therapeutics position peaked at $758K in Q3 2021.
  • 98 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2021.

Based on Parametric Portfolio Associates's 13F filing for Q4 2021, filed 15 Feb 2022.